Altre lingue Fortress Biotech, Inc.

Azioni

FBIO

US34960Q3074

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 24/04/2024			Variaz. 5gg	Var. 1 gen.
1,79 ^USD	-1,10%		+1,70%	-40,53%

28/03	Fortress Biotech, Inc. riporta i risultati degli utili per l'intero anno conclusosi il 31 dicembre 2023	CI
19/03	FORTRESS BIOTECH, INC. : Alliance Global Partners ottimista sul caso	ZM

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Avenue Therapeutics Announces Reverse Stock Split	24/04
North American Morning Briefing : Powell Awaited -2-	03/04
Certain Warrants of Fortress Biotech, Inc. are subject to a Lock-Up Agreement Ending on 2-APR-2024.	02/04
Certain Options of Fortress Biotech, Inc. are subject to a Lock-Up Agreement Ending on 2-APR-2024.	02/04
Certain Common Stock of Fortress Biotech, Inc. are subject to a Lock-Up Agreement Ending on 2-APR-2024.	02/04
Fortress Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights	28/03
Avenue Therapeutics to Host Virtual Key Opinion Leader Event on April 4, 2024	26/03
Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights	21/03
Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea	18/03
Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024	15/03
Journey Medical Corporation to Participate in the 36th Annual ROTH Conference	13/03
Fortress Biotech to Participate in 36th Annual ROTH Conference	12/03
Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting	11/03
Fortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS to Further Development of AAV-ATP7A Gene Therapy for Menkes Disease	04/03
Certain Preferred Stock of Fortress Biotech, Inc. are subject to a Lock-Up Agreement Ending on 8-FEB-2024.	08/02
Certain Common Stock of Fortress Biotech, Inc. are subject to a Lock-Up Agreement Ending on 8-FEB-2024.	08/02
Lindsay RosenwaldÃ¢€™s Fortress Bio (NASDAQ: FBIO) Spotlight on 2024 Milestones from Subsidiaries	02/02
Eric Rowinsky Announces Not Stand for Re-Election to the Board of Fortress Biotech, Inc	26/01
Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea	05/01

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Fortress Biotech, Inc.

Azioni

FBIO

US34960Q3074

Altre lingue

Filtri